◼ Archived
Business
🔮 fades ✓
Teva autoimmune antibody notches ph. 2 win in celiac disease
Teva's experimental antibody TEV-408 hits a key phase IIa endpoint in celiac disease studies.
Teva
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Teva
This hub groups 3 separate news trends connected to Teva, spanning August 28, 2026 through September 3, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 19 article observations and 19 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
FDA approves new use of popular diabetes drug
The FDA's approval of a new use for the diabetes drug Mounjaro is trending, with five outlets reporting on the expanded indication.
◼ Archived
Business
Genentech doubles down on ADC-resistance via $1B DualityBio pact
Genentech's $1B bet on DualityBio's ADC technology signals a major shift in cancer treatment strategies.